Physicians' Academy for Cardiovascular Education
AHA 2018 Deepak Bhatt considers the compounds that were tested in the VITAL and REDUCE-IT trials, which yielded neutral and very positive results, respectively, and what likely caused this discrepancy.
AHA 2018 Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.
AHA 2018 The pilot TRED-HF study evaluated a phased withdrawal of HF therapy in patients who responded well to therapy and found that this likely reflects remission rather than full recovery.
AHA 2018 Post-hoc analyses of the ODYSSEY OUTCOMES trial showed reduced all-cause mortality with alirocumab vs statins in patients with ACS, especially in those with LDL-c of ≥100 mg/dL at baseline.
AHA 2018 The TRED-HF evaluated well monitored withdrawal of pharmacological HF therapy and found that about 40% of patients deemed to have recovered DCM showed relapse.
AHA 2018 In Japanese patients aged ≥75 years with elevated LDL-c levels, ezetimibe results in prevention of atherosclerotic CV events, as shown in the EWTOPIA75 randomized trial.
AHA 2018 The Federal physical activity guidance stresses the importance and feasibility of incorporating more physical activity in daily life for all ages, and highlights all preventive benefits of physical activity.
AHA 2018 The results of the PIONEER-HF trial support the in-hospital initiation of sacubitril/valsartan in stabilized patients with acute decompensated heart failure and reduced EF.
AHA 2018 Yoga-CaRe is safe, feasible and significantly improves quality of life and return to pre-infarct daily activities. The per-protocol analysis suggests that yoga does lower CV events in adherent patients.
AHA 2018 A randomized phase 2b trial showed safety and efficacy of the antisense nucleotide AKCEA-APO(a)-Lrx at reducing Lp(a) levels in patients with CVD.
AHA 2018 The VITAL trial tested the effect of vitamin D and/or omega-3 supplementation on CVD and cancer outcomes in a large primary prevention cohort, and found few benefits of either product.
AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.
